Clinical Study Fuels Optimism for Sensus Healthcare Shares
24.09.2025 - 08:45:04 | boerse-global.de
A recent publication in the medical journal Dermatologic Therapy has provided a significant boost to the investment thesis for Sensus Healthcare. The study offers clinical validation for the efficacy of the company’s superficial radiation therapy (SRT), especially when used alongside a punch excision procedure for treating keloid scars.
This retrospective analysis, which involved 60 patients, demonstrated substantial scar improvement after a one-year period. Participants reported notable reductions in pain and itching, alongside decreased scar thickness and irregularity. Critically, the treatment was well-tolerated with no serious adverse effects recorded.
Joe Sardano, Chief Executive Officer of Sensus Healthcare, highlighted the study’s importance for convincing payers and policymakers. He stated that this evidence strengthens the market position of the company’s core technology within the dermatology... Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt kostenlos anmelden
Jetzt abonnieren.
